Recruiting
An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread - CA020-002
Updated: 05 June, 2019 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - Must have received and progressed on or failed one standard/approved treatment for cancer type, if available - At least 4 weeks since any previous treatment for cancer - Subject must consent to pretreatment and on treatment tumor biopsies - At least one lesion with measurable disease at baseline - Adequate organ and marrow function Exclusion Criteria: - Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted - Prior organ transplant - Participants with second/other active cancers requiring current treatment - Uncontrolled/significant heart disease - History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS) - Active/uncontrolled autoimmune disease - Active infection Other protocol defined inclusion/exclusion criteria could apply
